Health Care

Analysts Say; Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) to achieve $6.88 Price Target

0 47

Shares of Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) climbed +6.90% and ended at $4.49 greater than previous closing price of $4.20. The total 2.21 million shares were bought and sold throughout the most recent trading session more than average volume of 1.66 million shares.

Keryx Biopharmaceuticals, Inc. (KERX):

Currently Keryx Biopharmaceuticals, Inc. (KERX) captured an average recommendation of “ Hold ” from analysts, according to FactSet data. The stock has been suggested as “Buy” from “2″ Analysts”. “1” rated “Sell” for the company. “7” said the company as a “Hold”. Overweight rating was given by “1” and Underweight rating was given by “0”.

Analysts are expecting that the company to achieve $6.88 Price Target in next 52-weeks, average price is come up through the consensus of analysts. High potential price target is set at $11.00 however minimum price target advised by analysts is $3.00. The Median price target for the stock is measured at $7.00.

Presently, Analysts decided consensus EPS estimate of $-0.21 for present quarter and one month ago projected EPS estimate was at $-0.21. If we take a look at back 3 month ago, consensus EPS estimate was $-0.17.

A current consensus EPS estimate for next quarter is at $-0.21 and 3 month ago EPS forecast was $-0.14. Have a look at back 1 month ago, consensus EPS forecast was seen at $-0.21.

For current fiscal year, most recent EPS estimate is set at $-1.23 based on Analyst consensus and three month ago consensus EPS opinions was at $-0.95. During period one month ago, consensus EPS forecast was decided at $-1.22.

A current consensus EPS projection for next fiscal year is observed at $-0.56 and one month ago consensus EPS forecast was at $-0.56. Take a look at back three month ago, consensus EPS estimate opinions was decided at $-0.31 by analysts.

One Month ago, the stock has gained consensus mean rating of Hold based on the analysis of brokerage analyst firms polled. 2 presented the recommendations about the stock as a “Buy” signal and “Overweight” signal was reported by 1. 7 advised the “Hold” rating about this stock. 1 revealed “Sell” signal and “Underweight” rating was declared by 0.

Three Months Ago, Analysts recommended an average brokerage rating of Overweight derived from brokerage firms, according to FactSet. 6 said a “Buy Rating” and 1 announced “Overweight Rating”. 3 advised “Hold Rating” regarding the stock. 1 announced “Sell Rating” and 0 disclosed “Underweight Rating”.


About the author / 

Leave a reply

Your email address will not be published. Required fields are marked *

About Us

WSnews4investors is the influential source for financial news and Opinion Company with content which delivered over the Internet. WSnews4investors is a dynamic and innovative financial media outlet that empowers investors with high-quality, unique content that is coveted by Wall Street’s traders.